We are live on ! Find out more
ACHN

Achillion Pharmaceuticals
ACHN

Delisted

ACHN was delisted on the 27th of January, 2020.

Back to rankings

162 hedge funds and large institutions have $873M invested in Achillion Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 57 increasing their positions, 44 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

196% more call options, than puts

Call options by funds: $13M | Put options by funds: $4.38M

178% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 9

30% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 44

10% more funds holding

Funds holding: 147 → 162 (+15)

2% more capital invested

Capital invested by funds: $852M → $873M (+$20.3M)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
162
Holders Change
+15
Holders Change %
+10.2%
% of All Funds
4.32%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
25
Increased
57
Reduced
44
Closed
9
Calls
$13M
Puts
$4.38M
Net Calls
+$8.59M
Net Calls Change
+$2.19M

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$12.9M
2
O
OrbiMed
New York
+$12.1M
3
PA
Perceptive Advisors
New York
+$7.9M
4
TCP
Tourbillon Capital Partners
New York
+$7.88M
5
NI
Numeric Investors
Massachusetts
+$7.6M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$37.4M
2
Millennium Management
Millennium Management
New York
-$26.9M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$16.4M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$15.9M
5
JP Morgan Chase
JP Morgan Chase
New York
-$5.14M
Name Holding Trade Value Shares
Change 		Change in
Stake
KF
151
Krilogy Financial
Missouri
$5K – – –
TCIM
152
TIAA CREF Investment Management
New York
$4.05K +$147K +17,316 +4%
IA
153
IFP Advisors
Florida
$4K – – –
Bank of Montreal
154
Bank of Montreal
Ontario, Canada
$3K – – –
EFSCE
155
Enterprise Financial Services Corp (EFSC)
Missouri
$3K – – –
GAM
156
Gemmer Asset Management
California
$2K – – –
LTFS
157
Ladenburg Thalmann Financial Services
Florida
$2K – – –
NFG
158
Next Financial Group
Texas
$2K – – –
Carson Wealth (CWM LLC)
159
Carson Wealth (CWM LLC)
Nebraska
$1K +$638 +75 New
TRCT
160
Tower Research Capital (TRC)
New York
$1K +$850 +100 New
VOYA Investment Management
161
VOYA Investment Management
Georgia
$398 – – –
Marshall Wace
162
Marshall Wace
United Kingdom
– -$4.22M -540,611 Closed
GAM
163
Gotham Asset Management
New York
– -$1.5M -191,792 Closed
CS
164
Candriam SCA
Luxembourg
– -$1.15M -148,000 Closed
QIM
165
Quantitative Investment Management
Virginia
– -$763K -97,900 Closed
DTL
166
Dynamic Technology Lab
Singapore
– -$433K -55,521 Closed
Balyasny Asset Management
167
Balyasny Asset Management
Illinois
– -$180K -23,100 Closed
AL
168
Airain Ltd
Guernsey
– -$176K -22,554 Closed
PAM
169
Princeton Alpha Management
New Jersey
– -$109K -13,912 Closed
BAM
170
Brave Asset Management
New Jersey
– -$36K -4,600 Closed
3 4 5 6
7

ACHN Hedge Fund Activity: Q3 2016 in Review

162 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q3 2016, worth a combined $873M — up 2.4% from $852M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new ACHN positions and 9 closed out — a net gain of 16 holders — while 57 added to existing stakes and 44 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $12.9M. The largest seller was Fidelity Investments, cutting an estimated $37.4M.

  • 162 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q3 2016, up from 147 in Q2 2016.
  • Funds reported $873M of Achillion Pharmaceuticals stock for Q3 2016, up 2.4% quarter-over-quarter.
  • 25 funds opened new Achillion Pharmaceuticals positions in Q3 2016 and 9 closed out, a net change of +16 holders.
  • The largest Achillion Pharmaceuticals buyer in Q3 2016 was Goldman Sachs, an estimated $12.9M added.
  • The largest Achillion Pharmaceuticals seller in Q3 2016 was Fidelity Investments, an estimated $37.4M sold.

Based on aggregated 13F filings for Q3 2016.